We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PolyTherics and Critical Pharmaceuticals Enter Drug Development Collaboration with Funding from the Technology Strategy Board
News

PolyTherics and Critical Pharmaceuticals Enter Drug Development Collaboration with Funding from the Technology Strategy Board

PolyTherics and Critical Pharmaceuticals Enter Drug Development Collaboration with Funding from the Technology Strategy Board
News

PolyTherics and Critical Pharmaceuticals Enter Drug Development Collaboration with Funding from the Technology Strategy Board

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PolyTherics and Critical Pharmaceuticals Enter Drug Development Collaboration with Funding from the Technology Strategy Board"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Critical Pharmaceuticals and PolyTherics Limited have announced a collaboration to develop a novel injectable sustained release drug delivery system for a high value biological drug. The companies have been awarded a grant from the government-backed Technology Strategy Board to develop the technology and prototype drug.

The aim of the collaboration is to produce a clinically superior sustained release product that can be administered less frequently than currently marketed products, with a potential reduction in side effects and improved overall efficacy.

Professor Lisbeth Illum, Chief Executive Officer of Critical Pharmaceuticals commented: “We are delighted to be working with PolyTherics to address a significant need for improved biotechnology products. The technology we develop together has the potential to create an enhanced delivery platform for a wide range of biological drugs that will provide an attractive alternative to frequent injections for patients, clinicians and healthcare providers.”

The project is scheduled to run for two years with a total budget of just under £700,000; the Technology Strategy Board will meet half the costs to support the development of the technology and a novel long acting product up to proof of concept in an established disease model.

Dr Keith Powell, Chief Executive Officer, commented “This joint project gives us an opportunity to develop a unique technology and we are delighted to have received this additional support from the Technology Strategy Board to enable us to work with Critical Pharmaceuticals to produce a better product for patients”.

Advertisement